Effect of Meal Composition and Timing on Evobrutinib Bioavailability

Phase 1 Completed 20 enrolled Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

RandomizedCrossoverOpen-labelOther

Summary

This study will evaluate the Pharmacokinetics (PK) of the Phase II tablet formulation of Evobrutinib under fasted conditions, within 30 minutes after start of a light meal, one hour prior to start of a low-fat meal, and 2 hours after start of a low-fat meal.

Timeline

Start: 2019-04-15
Primary completion: 2019-06-12
Completion: 2019-06-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Evobrutinib	Small molecule	—	Oral

Indications

No indication recorded.